JMIR formative research

Using Apps and Wearables to Remotely Monitor Myasthenia Gravis Patients and Their Doctors: Feasibility and Usability

Updated

Abstract

Adherence rates for remote monitoring of myasthenia gravis patients ranged from 74.3% to 97.9% across different data types.

  • Patients demonstrated the highest adherence for patient-reported outcome measures at 96.6%.
  • Spirometry adherence was 87.7%, while wearable device adherence was 80.9%.
  • Patients engaged with the wearable device significantly longer than required, averaging 20 hours per day.
  • Most patients expressed a desire to continue using the telemedicine app.
  • User satisfaction scores indicated 'excellent usability,' with a median score of 85 on the System Usability Scale.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflicts of Interest: MS has received speaker's honoraria and honoraria for attendance at advisory boards from Argenx and Alexion. MH has received speaker´s honoraria from Argenx and speaker’s honoraria and honoraria for attendance at advisory boards from Alexion. PN has received grant support from PCORI, Alexion, Dianthus, and Janssen. PN has received honoraria for consulting services for Alexion, Argenx, CVS Caremark, Dianthus, GSK, Immune Abs, Janssen, Novartis, and UCB. PN has served on DSMB for Sanofi. AM received speaker's honoraria from Alexion, Grifols, and Hormosan, and honoraria from Argenx, Alexion, MorphoSys, and UCB for consulting services, and financial research support from Alexion and Octapharma. He is chairperson of the medical advisory board of the DMG. SL has received speaker's honoraria for attendance at patient events and advisory boards from Argenx, Alexion, Biogen, Hormosan, Roche, and UCB. None declared by other authors.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free